
TRIUMPH-3 pharmacokinetic data show once-daily trientine tetrahydrochloride achieved exposure comparable to twice-daily dosing for Wilson disease.

Michael Schilsky, MD, is a professor of medicine and medical director of adult liver transplant at Yale-New Haven Transplantation Center.

TRIUMPH-3 pharmacokinetic data show once-daily trientine tetrahydrochloride achieved exposure comparable to twice-daily dosing for Wilson disease.

Real-world REASON data suggest NCC-Sp, a measure of bioavailable copper, can track treatment response across therapies in unstable Wilson disease.

Data presented at AASLD 2025 show patients without severe neurologic involvement can achieve cognitive improvement with early detection and therapy.

Schilsky describes lingering challenges and unmet needs in Wilson disease and highlights recent innovations in monitoring and diagnosis.

Schilsky provides an overview of Wilson disease and describes optimal management strategies, highlighting the importance of early detection and intervention.